Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000032:analysis*; D024042:Collagen Type I / Q000652:urine; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016015:Logistic Models; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010446:Peptide Fragments / Q000187:drug effects*; D011347:Procollagen / Q000187:drug effects*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D012307:Risk Factors; D016103:Spinal Fractures / Q000517:prevention & control*
D015415:Biomarkers; D024042:Collagen Type I; D004965:Estrogen Antagonists; D010446:Peptide Fragments; D011347:Procollagen; C047202:procollagen Type I N-terminal peptide; D015675:Osteocalcin; D020849:Raloxifene Hydrochloride; D000469:Alkaline Phosphatase